4//SEC Filing
Tade Brad L. 4
Accession 0001140361-25-005536
CIK 0001368514other
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 9:01 PM ET
Size
8.8 KB
Accession
0001140361-25-005536
Insider Transaction Report
Form 4
Tade Brad L.
CFO and Treasurer
Transactions
- Award
Common Stock
2025-02-19+62,227→ 261,660 total - Award
Stock Option (right to buy)
2025-02-19+93,023→ 93,023 totalExercise: $16.07Exp: 2035-02-19→ Common Stock (93,023 underlying)
Footnotes (5)
- [F1]These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.
- [F2]Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 72,400 RSUs granted on July 24, 2024, that will vest in four equal installments (25% per installment) on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
- [F3](continued from footnote 2) (iii) 56,250 unvested RSUs, granted by the Company on June 26, 2023, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting;
- [F4](continued from footnote 3) (iv) 50,000 RSUs, all of which are currently unvested, granted by the Company on February 26, 2024, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, which RSUs will be settled into common stock upon vesting; and (v) 20,783 shares acquired in open market purchases and pursuant to the vesting of RSUs.
- [F5]The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan.
Documents
Issuer
ADMA BIOLOGICS, INC.
CIK 0001368514
Entity typeother
Related Parties
1- filerCIK 0002030561
Filing Metadata
- Form type
- 4
- Filed
- Feb 20, 7:00 PM ET
- Accepted
- Feb 21, 9:01 PM ET
- Size
- 8.8 KB